The development of BCR::ABL1-targeting tyrosine kinase inhibitors (TKIs) has led to substantial improvements in clinical outcomes for patients with chronic myeloid leukemia (CML) [1–6]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.